Optogenetic control over transgene expression for the therapy of brain and spine
Localized Therapeutics, Llc, San Diego CA
Investigators
Linked publications & trials
Abstract
Optogenetic control over transgene expression for the therapy of brain and spine Abstract Gene modified stem cells are a powerful tool for the production of secretable therapeutic proteins in the body. Yet, there is a valid concern over their safety since there is no way to control them once they have been transplanted. We propose to utilize optogenetic control of transcription (ORT) to externally control secretion of the therapeutic protein using red light. ORT would improve the efficacy and safety of the therapy by repeated remote activation of transgene synthesis with red light delivered noninvasively. For a specific disease application, we propose to use intrathecally delivered ORTdriven stem cells to produce antiinflammatory antiTNF hybrid antibodies in the subarachnoid cavity for the therapy of neuroinflammation in the brain. The ORT option would allow us to externally induce production of the antiinflammatory antibody using red light as needed. At this initial phase of the project, we propose the conceptual evaluation of the ORT system genetically embedded into bone marrow stem cells. This testing is proposed in cell culture (Aim 1) and the mouse cerebral subarachnoid cavity (Aim 2). The proposed method aims to improve the safety and efficiency of the therapy of chronic CNS disorders with episodic neuroinflammatory components by providing the benefit of remote control of the timing and dosage of the therapy.
View original record on NIH RePORTER →